Automate Your Wheel Strategy on FGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including FGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FGEN
- Rev/Share -0.2332
- Book/Share -1.7328
- PB -4.1725
- Debt/Equity 0.0
- CurrentRatio 2.0238
- ROIC -1.4591
- MktCap 29221925.0
- FreeCF/Share -0.7552
- PFCF -0.3833
- PE -72.9387
- Debt/Assets 0.0
- DivYield 0
- ROE 0.048
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence R&D Duchenne Muscular Dystrophy. The …
Read More
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Read More
About FibroGen, Inc. (FGEN)
- IPO Date 2014-11-14
- Website https://www.fibrogen.com
- Industry Biotechnology
- CEO Thane Wettig
- Employees 225